Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Biodesix
BDSX
Biodesix
Lung Diagnostics Will Face Regulatory Delays While Modest Progress Unfolds
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.50
73.6% undervalued
intrinsic discount
16 Aug
US$0.40
Loading
1Y
-77.2%
7D
-1.0%
Author's Valuation
US$1.5
73.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.5
73.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-66m
129m
2018
2020
2022
2024
2025
2026
2028
Revenue US$128.5m
Earnings US$6.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
16.21%
Healthcare Services revenue growth rate
0.27%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.57%
Calculation
US$6.78m
Earnings '28
x
41.59x
PE Ratio '28
=
US$281.90m
Market Cap '28
US$281.90m
Market Cap '28
/
151.09m
No. shares '28
=
US$1.87
Share Price '28
US$1.87
Share Price '28
Discounted to 2025 @ 7.57% p.a.
=
US$1.50
Fair Value '25
